The post Bitcoin More ‘Undervalued’ Than During All Previous Bear Markets, Data Says appeared on BitcoinEthereumNews.com. Bitcoin’s MVRV Z-score printed record The post Bitcoin More ‘Undervalued’ Than During All Previous Bear Markets, Data Says appeared on BitcoinEthereumNews.com. Bitcoin’s MVRV Z-score printed record

Bitcoin More ‘Undervalued’ Than During All Previous Bear Markets, Data Says

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Bitcoin’s MVRV Z-score printed record lows on a rolling two-year basis, making BTC price more “undervalued” than at the pit of past bear markets.

Bitcoin (BTC) may be “close to the end” of its correction as a classic BTC price metric beats records.

Key points:

  • Bitcoin’s MVRV Z-score is at record lows on two-year rolling time frames.

  • The “wild” data is leading to predictions of an imminent BTC price recovery.

  • Analysis says that the precious metals rally is “done for now.”

MVRV Z-score says Bitcoin is “undervalued”

In an X post Friday, crypto trader, analyst and entrepreneur Michaël van de Poppe confirmed the lowest-ever readings for Bitcoin’s MVRV Z-score.

“This is a phenomenal chart,” he told followers about the data, sourced from crypto analyst James Easton.

Easton agreed that the chart now looks “wild,” having fallen to the lowest levels ever recorded.

MVRV refers to market value versus realized value, and measures the price at which the BTC supply last moved (realized cap) relative to the value of all BTC in existence (market cap). 

The Z-score divides that ratio by the standard deviation of market cap, giving clear “overvalued” and “undervalued” ranges for Bitcoin at a given point in time.

“The current Z-Score of $BTC is lower than during the bear market bottom in 2015, 2018, COVID crash 2020 and 2022,” Van de Poppe noted about rolling two-year time frames.

Bitcoin MVRV Z-Score. Source: Glassnode

Raw data from onchain analytics platform Glassnode puts the Z-score at its lowest levels since October 2023. At the time, BTC/USD traded at around $30,000.

The last time that the “live” Z-score dipped into its green “undervalued” zone was at the end of the last bear market in 2022.

Precious metals prep key BTC price “trigger”

Bitcoin price action fell to new two-month lows this week amid a sudden sell-off across risk assets and precious metals.

Related: Bitcoin trend line cross mimics 2022 amid ‘insane’ BTC vs. silver breakdown

BTC/USD hit $81,040, per data from TradingView, and at the time of writing was still down nearly 2% versus the daily open.

BTC/USD one-hour chart. Source: Cointelegraph/TradingView

Earlier, Cointelegraph reported on a prediction that the period around the January monthly close would see Bitcoin put in a long-term floor, similar to the end of previous bear markets.

Reacting, Van de Poppe said that both gold and silver were “done for now.”

“The markets are dropping massively, as they are down 10-15% the past 24 hours,” he wrote on X. 

This article does not contain investment advice or recommendations. Every investment and trading move involves risk, and readers should conduct their own research when making a decision. While we strive to provide accurate and timely information, Cointelegraph does not guarantee the accuracy, completeness, or reliability of any information in this article. This article may contain forward-looking statements that are subject to risks and uncertainties. Cointelegraph will not be liable for any loss or damage arising from your reliance on this information.

Source: https://cointelegraph.com/news/bitcoin-bear-market-almost-over-btc-price-metric-outpaces-2022-bottom?utm_source=rss_feed&utm_medium=feed&utm_campaign=rss_partner_inbound

SPACEX(PRE) Launchpad

SPACEX(PRE) LaunchpadSPACEX(PRE) Launchpad

Register for a chance to win a free lucky draw

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin is poised for a reversal if ETF demand returns or a ceasefire occurs, potentially crushing short sellers in a massive price squeeze.
Share
Coin Telegraph2026/04/04 19:58
Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Inertia is the invisible tax on modern industrial throughput. Every millisecond a robotic arm spends decelerating, or waiting for high-frequency vibrations to settle
Share
Techbullion2026/04/02 18:25

RealStocks Now Live

RealStocks Now LiveRealStocks Now Live

Trade real U.S. stock via regulated brokerage